IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

CASALI, PAOLO GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 18.910
NA - Nord America 12.228
AS - Asia 11.997
SA - Sud America 1.222
AF - Africa 215
OC - Oceania 102
Continente sconosciuto - Info sul continente non disponibili 10
Totale 44.684
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.774
DE - Germania 8.340
CN - Cina 4.283
GB - Regno Unito 3.841
SG - Singapore 3.441
IT - Italia 2.188
HK - Hong Kong 1.202
RU - Federazione Russa 935
BR - Brasile 903
VN - Vietnam 784
SE - Svezia 707
FR - Francia 683
BD - Bangladesh 544
IN - India 473
FI - Finlandia 398
IE - Irlanda 382
NL - Olanda 338
ES - Italia 324
JP - Giappone 304
CA - Canada 260
ID - Indonesia 218
KR - Corea 139
TR - Turchia 135
AT - Austria 104
BE - Belgio 102
MX - Messico 101
GR - Grecia 100
AU - Australia 94
AR - Argentina 90
DK - Danimarca 85
CI - Costa d'Avorio 83
UA - Ucraina 74
CH - Svizzera 68
PL - Polonia 64
IQ - Iraq 63
CO - Colombia 58
TW - Taiwan 56
PH - Filippine 51
EC - Ecuador 44
ZA - Sudafrica 40
SA - Arabia Saudita 39
PT - Portogallo 38
VE - Venezuela 35
PK - Pakistan 34
CL - Cile 31
UZ - Uzbekistan 31
IL - Israele 29
PE - Perù 28
RO - Romania 28
TH - Thailandia 23
AE - Emirati Arabi Uniti 22
CR - Costa Rica 17
MA - Marocco 17
MY - Malesia 17
NO - Norvegia 17
CZ - Repubblica Ceca 16
EG - Egitto 16
PY - Paraguay 16
JO - Giordania 14
GT - Guatemala 12
DO - Repubblica Dominicana 11
HN - Honduras 11
IR - Iran 11
JM - Giamaica 11
TN - Tunisia 11
AL - Albania 10
KE - Kenya 10
NP - Nepal 10
BG - Bulgaria 9
OM - Oman 9
SK - Slovacchia (Repubblica Slovacca) 9
UY - Uruguay 9
AZ - Azerbaigian 8
BO - Bolivia 8
MK - Macedonia 8
EU - Europa 7
KZ - Kazakistan 7
PA - Panama 7
CU - Cuba 6
ET - Etiopia 6
HR - Croazia 6
HU - Ungheria 6
LB - Libano 6
LU - Lussemburgo 6
NZ - Nuova Zelanda 6
TT - Trinidad e Tobago 6
BA - Bosnia-Erzegovina 5
LT - Lituania 5
NG - Nigeria 5
PS - Palestinian Territory 5
BY - Bielorussia 4
DZ - Algeria 4
KG - Kirghizistan 4
KW - Kuwait 4
MU - Mauritius 4
QA - Qatar 4
SN - Senegal 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AM - Armenia 3
CG - Congo 3
Totale 44.624
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 7.707
Southend 3.473
Singapore 1.958
Ashburn 1.168
Hong Kong 1.043
Chandler 767
San Jose 757
Fairfield 736
Milan 688
Seattle 591
Beijing 551
Council Bluffs 466
Princeton 428
Wilmington 415
Dublin 374
Houston 361
Woodbridge 333
Los Angeles 323
Santa Clara 315
Guangzhou 300
Cambridge 288
Dallas 276
Ho Chi Minh City 259
Helsinki 252
New York 249
Ann Arbor 243
Lauterbourg 242
Nanjing 234
Dearborn 216
Shanghai 208
Redwood City 201
Hanoi 199
Des Moines 172
Hangzhou 167
Buffalo 162
Jakarta 159
Moscow 147
Jinan 146
Bengaluru 143
Munich 141
Tokyo 141
Phoenix 123
Rome 121
Hefei 113
Madrid 109
Toronto 107
Columbus 101
Tianjin 99
Boardman 96
Shenyang 92
The Dalles 87
Abidjan 82
São Paulo 81
Cangzhou 79
Nuremberg 77
Changsha 76
Chicago 74
Seoul 74
Nanchang 70
Shenzhen 70
London 65
Fuzhou 58
Istanbul 57
Atlanta 52
Plymouth 52
Naples 51
San Diego 50
Bologna 49
Hebei 49
Brussels 48
Central District 45
Vienna 45
Amsterdam 43
Washington 43
Da Nang 42
Wuhan 39
Hyderabad 37
Jiaxing 37
Turin 37
Taipei 35
Zhengzhou 35
Montreal 33
Berlin 32
Haiphong 32
Paris 32
Barcelona 31
Boston 30
Silver Spring 30
Baghdad 29
Pune 27
Qingdao 27
San Francisco 27
Rio de Janeiro 26
Turku 26
Chennai 25
Mexico City 25
Orem 25
Redmond 25
Bari 24
Chengdu 24
Totale 30.229
Salva come PNG Salva come JPEG
Nome #
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment : a non-randomised phase 2 clinical trial 1.132
Global cancer control: responding to the growing burden, rising costs and inequalities in access 847
Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up 845
Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up 719
High-grade soft-tissue sarcomas: Tumor response assessment - Pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria 651
Biosimilars : a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers 645
Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up 542
A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113) 430
High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma 378
Primary extremity soft tissue sarcomas: Outcome improvement over time at a single institution 377
How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience 356
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016 349
NR4A3 fusion proteins trigger an axon guidance switch that marks the difference between EWSR1 and TAF15 translocated extraskeletal myxoid chondrosarcomas 333
Combination of PPARg agonist pioglitazone and trabectedin induce adipocyte differentiation to overcome trabectedin resistance in myxoid liposarcomas 329
The management of desmoid tumours : A joint global consensus-based guideline approach for adult and paediatric patients 326
Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups 324
Response to sunitinib malate in advanced alveolar soft part sarcoma 318
Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors 305
Best practices for the management of local-regional recurrent chordoma : a position paper by the Chordoma Global Consensus Group 303
Solitary fibrous tumour presenting with a single bone metastasis : report of six cases and literature review 299
Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study 282
Activity of anthracycline- and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma 279
Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma : A Multicenter, International, Retrospective Study 278
Trabectedin use in soft-tissue sarcoma patients in a real-world setting: Data from an Italian national drug-access registry 275
Imatinib mesylate in chordoma 275
Epithelioid hemangioendothelioma, an ultra-rare cancer : a consensus paper from the community of experts 271
High-Dose Ifosfamide Chemotherapy in a Series of Patients Affected by Myxoid Liposarcoma 269
Evaluating the effectiveness of clinical ethics committees : a systematic review 267
Role of chemotherapy, VEGFR inhibitors and mTOR Inhibitors in advanced Perivascular Epithelioid Cell Tumours (PEComas) 266
PATIENT VOICES, a project for the integration of the systematic assessment of patient reported outcomes and experiences within a comprehensive cancer center: a protocol for a mixed method feasibility study 263
Identification of a gene expression driven progression pathway in Myxoid liposarcoma 260
CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 study 259
Anthracycline-based and gemcitabine-based chemotherapy in the adjuvant setting for stage I uterine leiomyosarcoma: a retrospective analysis at two reference centers 259
Solitary fibrous tumor of all sites: outcome of late recurrences in 14 patients 251
Response to isolated limb perfusion and chemotherapy with epirubicin plus ifosfamide in a metastatic malignant ossifying fibromyxoid tumor 244
Identification of SRF-E2F1 fusion transcript in EWSR-negative myoepithelioma of the soft tissue 244
Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RAS-P WT GIST 244
The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors : A Multicenter, European Retrospective Case Series Analysis 242
Identification of an actionable mutation of kit in a case of extraskeletal myxoid chondrosarcoma 240
Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment 238
Pazopanib for metastatic soft-tissue sarcoma (PALETTE) : a randomised, double-blind, placebo-controlled phase 3 trial 237
The GOLD ReGISTry: A Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours 236
Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma 236
ECCO Essential Requirements for Quality Cancer Care: Soft Tissue Sarcoma in Adults and Bone Sarcoma : a critical review 235
Completion surgery of residual disease after primary inadequate surgery of retroperitoneal sarcomas can salvage a selected subgroup of patients—A propensity score analysis 235
Comparative assessment of antitumor effects and autophagy induction as a resistance mechanism by cytotoxics and EZH2 inhibition in INI1-negative epithelioid sarcoma patient-derived xenograft 235
Adequate Local Control in High-Risk Soft Tissue Sarcoma of the Extremity Treated with Surgery Alone at a Reference Centre : Should Radiotherapy Still be a Standard? 235
Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers : a European consensus position paper 233
Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors 230
Mode of action of trabectedin in myxoid liposarcomas 229
Localised thoracic sarcomas : outcome improvement over time at a single institution 227
Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells 226
Rechallenge of denosumab in advanced giant cell tumor of the bone after atypical femur fracture: A case report and review of literature 225
Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas 224
Histology-Specific Nomogram for Primary Retroperitoneal Soft Tissue Sarcoma 220
Ethical issues in oncology practice: a qualitative study of stakeholders' experiences and expectations 217
2018 ESMO Sarcoma and GIST Symposium: take-home messages' in soft tissue sarcoma 215
Data protection and research in the European Union: a major step forward, with a step back 214
Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib 213
Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS) : long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group 211
The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma : revisiting the results of the EORTC-STBSG 62931 randomised trial 211
A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake 208
Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib : a case report 208
Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study 208
Clinical prognostic factors in advanced epithelioid haemangioendothelioma : a retrospective case series analysis within the Italian Rare Cancers Network 207
Phase 2 study for nonmetastatic extremity high-grade osteosarcoma in pediatric and adolescent and young adult patients with a risk-adapted strategy based on ABCB1/P-glycoprotein expression: An Italian Sarcoma Group trial (ISG/OS-2) 206
Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: A case series analysis and literature review 206
Genome-wide analysis identifies MEN1 and MAX mutations and a neuroendocrine-like molecular heterogeneity in Quadruple WT GIST 203
Anthracycline, gemcitabine, and pazopanib in epithelioid sarcoma : a multi-institutional case series 203
Guidelines for time-to-event endpoint definitions in sarcomas and gastro-intestinal stromal tumors (GIST) trials. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) 203
Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour 201
Management of complicated tumor response to tyrosine-kinase inhibitors in gastrointestinal stromal tumors 200
Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study 199
Hope in cancer patients : The relational domain as a crucial factor 197
Role of macrophage targeting in the antitumor activity of trabectedin 197
Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities 197
Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient [3] 196
Is autophagy rather than apoptosis the regression driver in imatinib-treated gastrointestinal stromal tumors? 194
High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial 193
Pazopanib for treatment of typical solitary fibrous tumours : a multicentre, single-arm, phase 2 trial 193
Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down‐regulation 191
The natural history of epithelioid sarcoma. A retrospective multicentre case-series within the Italian Sarcoma Group 190
Epithelioid peritoneal mesothelioma : a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework 188
Impact of perioperative chemotherapy and radiotherapy in patients with primary extremity soft tissue sarcoma: retrospective analysis across major histological subtypes and major reference centres 188
Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: A case-series analysis within the Italian rare cancer network 188
Analyzing the "careGap" : assessing gaps in adherence to clinical guidelines in adult soft tissue sarcoma 186
Dacarbazine in solitary fibrous tumor : a case series analysis and preclinical evidence vis-à-vis temozolomide and antiangiogenics 186
Ten-year progression-free and overall survival in patients with unresectable or metastatic GI stromal tumors : long-term analysis of the european organisation for research and treatment of cancer, Italian sarcoma group, and Australasian gastrointestinal trials group intergroup phase III randomized trial on imatinib at two dose levels 185
Impact of pathological stratification on the clinical outcomes of advanced well‐differentiated/dedifferentiated liposarcoma treated with trabectedin 185
Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour 184
Prolonged activity and toxicity of sirolimus in a patient with metastatic renal perivascular epithelioid cell tumor : a case report and literature review 182
Sporadic desmoid-type fibromatosis: A stepwise approach to a non-metastasising neoplasm-A position paper from the Italian and the French Sarcoma Group 181
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST : a retrospective analysis 180
Current models, challenges and best practices for work conducted between European academic cooperative groups and industry 180
Rationale of the rare cancer list : a consensus paper from the Joint Action on Rare Cancers (JARC) of the European Union (EU) 179
Risks of the new EU Data protection regulation : an ESMO position paper endorsed by the European oncology community 178
Building a global consensus approach to chordoma : a position paper from the medical and patient community 176
Quality of life assessment and clinical decision-making 175
Magnetic resonance imaging patterns of tumor response to chemotherapy in desmoid-type fibromatosis 172
Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib 171
Totale 27.222
Salva come PNG Salva come JPEG
Categoria #
all - tutte 109.769
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 109.769
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021481 0 0 0 0 0 0 0 0 0 0 311 170
2021/20222.526 198 205 135 130 193 170 138 190 232 209 170 556
2022/20233.032 402 306 333 291 313 539 92 169 279 63 164 81
2023/20247.233 114 158 134 136 454 242 1.168 996 513 1.007 1.131 1.180
2024/20258.410 1.035 1.256 859 895 409 345 248 613 401 534 595 1.220
2025/202612.950 1.038 731 989 948 1.208 1.036 1.766 950 1.822 925 1.537 0
Totale 46.434